Charles Schwab
ZBIO

Charles Schwab’s Zenas BioPharma ZBIO Stock Holding History

Charles Schwab’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.39M Buy
224,402
+11,209
+5% +$252K ﹤0.01% 2456
2025
Q4 		$7.74M Buy
213,193
+34,797
+20% +$1.14M ﹤0.01% 2254
2025
Q3 		$3.96M Buy
178,396
+56,186
+46% +$915K ﹤0.01% 2531
2025
Q2 		$1.18M Buy
122,210
+6,070
+5% +$59.1K ﹤0.01% 2847
2025
Q1 		$918K Sell
116,140
-2,520
-2% -$19.7K ﹤0.01% 2869
2024
Q4 		$972K Buy
+118,660
New +$1.85M ﹤0.01% 2924

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Charles Schwab's ZBIO Position: Q1 2026 in Review

Charles Schwab increased its Zenas BioPharma (ZBIO) stake by 5.3% in Q1 2026, buying an estimated $252K and bringing the position to 224,402 shares worth $4.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2456.

Charles Schwab first reported a position in ZBIO in Q4 2024 and has held it in 6 quarters since. The position peaked at $7.74M in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Charles Schwab held 224,402 shares of Zenas BioPharma worth $4.39M as of Q1 2026.
  • Charles Schwab bought 11,209 Zenas BioPharma shares in Q1 2026, an estimated $252K.
  • Zenas BioPharma made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #2456 holding.
  • Charles Schwab first reported a position in Zenas BioPharma in Q4 2024 and has held it in 6 quarters since.
  • Charles Schwab's Zenas BioPharma position peaked at $7.74M in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.